Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
4.020
+0.120 (3.08%)
Oct 28, 2025, 4:00 PM EDT - Market closed
Pluri Revenue
In the fiscal year ending June 30, 2025, Pluri had annual revenue of $1.34M with 309.82% growth. Pluri had revenue of $398.00K in the quarter ending June 30, 2025, with 314.58% growth.
Revenue (ttm)
$1.34M
Revenue Growth
+309.82%
P/S Ratio
19.02
Revenue / Employee
$9,408
Employees
142
Market Cap
32.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.34M | 1.01M | 309.82% |
| Jun 30, 2024 | 326.00K | 39.00K | 13.59% |
| Jun 30, 2023 | 287.00K | 53.00K | 22.65% |
| Jun 30, 2022 | 234.00K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PLUR News
- 5 months ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 6 months ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 8 months ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 8 months ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 9 months ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 11 months ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 1 year ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 1 year ago - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PRNewsWire